6,734 Shares in McKesson Corporation $MCK Bought by Deane Retirement Strategies Inc.

Key Points

• Deane Retirement Strategies purchased 6,734 McKesson shares worth approximately $5.1 million, making the stock about 2.2% of its portfolio. Institutional investors collectively own 85.07% of McKesson.
• McKesson exceeded quarterly expectations, reporting adjusted EPS of $9.93 and revenue of $105.38 billion, up 7.7% year over year. Specialty pharmaceuticals helped drive a 19% increase in pharmaceutical profit, and the company raised fiscal 2027 EPS guidance to $44.20–$45.00.
• Shareholder returns are increasing as McKesson plans roughly $5 billion in buybacks and raised its quarterly dividend 15% to $0.94. Wall Street maintains a “Moderate Buy” consensus with an average price target of $968.93.

Deane Retirement Strategies Inc. purchased a new position in shares of McKesson Corporation (NYSE:MCK - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,734 shares of the company's stock, valued at approximately $5,086,000. McKesson makes up approximately 2.2% of Deane Retirement Strategies Inc.'s holdings, making the stock its 19th largest holding.

Other hedge funds also recently made changes to their positions in the company. Arista Wealth Management LLC grew its stake in shares of McKesson by 1.0% in the 2nd quarter. Arista Wealth Management LLC now owns 1,446 shares of the company's stock valued at $1,093,000 after purchasing an additional 14 shares during the period. Everpar Advisors LLC lifted its position in shares of McKesson by 8.1% during the 2nd quarter. Everpar Advisors LLC now owns 683 shares of the company's stock worth $516,000 after buying an additional 51 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in shares of McKesson by 16.9% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 11,124 shares of the company's stock worth $8,405,000 after buying an additional 1,611 shares during the period. Breakwater Capital Group boosted its stake in McKesson by 18.3% in the 2nd quarter. Breakwater Capital Group now owns 555 shares of the company's stock valued at $419,000 after buying an additional 86 shares in the last quarter. Finally, Valeo Financial Advisors LLC boosted its stake in McKesson by 11.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,160 shares of the company's stock valued at $876,000 after buying an additional 116 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company's stock.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
• Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

McKesson Stock Up 0.2%

Shares of NYSE MCK opened at $871.72 on Monday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The firm's 50-day simple moving average is $800.68 and its 200 day simple moving average is $840.99. The company has a market cap of $101.63 billion, a price-to-earnings ratio of 23.33, a price-to-earnings-growth ratio of 1.71 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $105.38 billion during the quarter, compared to analysts' expectations of $103.88 billion. During the same quarter last year, the company posted $8.26 EPS. The company's quarterly revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities analysts expect that McKesson Corporation will post 44.59 earnings per share for the current year.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be issued a $0.94 dividend. This is an increase from McKesson's previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 1st. McKesson's dividend payout ratio (DPR) is 8.78%.

Wall Street Analyst Weigh In

MCK has been the subject of several recent analyst reports. Evercore reiterated an "outperform" rating on shares of McKesson in a research note on Thursday. Citigroup upped their target price on shares of McKesson from $945.00 to $1,000.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $875.00 target price on shares of McKesson in a research report on Friday, May 8th. Barclays reduced their price target on shares of McKesson from $1,050.00 to $925.00 and set an "overweight" rating on the stock in a research report on Wednesday, June 10th. Finally, Wall Street Zen lowered shares of McKesson from a "buy" rating to a "hold" rating in a report on Saturday, June 27th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, McKesson has an average rating of "Moderate Buy" and a consensus target price of $968.93.

Insider Activity at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the company's stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total transaction of $101,612.00. Following the transaction, the chief accounting officer owned 632 shares of the company's stock, valued at approximately $482,848. This represents a 17.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the transaction, the executive vice president owned 3,247 shares in the company, valued at $2,471,259.23. The trade was a 52.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 28,748 shares of company stock worth $22,262,035. Company insiders own 0.06% of the company's stock.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source